- Business
- SHL Telemedicine Ltd. develops and markets personal telemedicine solutions focused on remote monitoring and diagnosis of cardiovascular and chronic conditions; it provides devices such as SmartHeart, a mobile 12-lead ECG for heart attack detection; CardioSen’C, a cellular-digital 12-lead ECG transmitter; Cardio’B, a portable 12-lead ECG device; TelePress, a remote blood pressure monitor; central communication modules integrating data from blood pressure, weight scales, TelePulse Oximeter for oxygen saturation, TeleBreather for breath exhalation, and glucose meters; and telemedicine services including congestive heart failure monitoring, COPD management, and medical call center support delivered via electronic and telecommunication technologies. The company serves physicians, hospitals, health insurance funds, and patients in Israel, Europe including Germany, and internationally from its headquarters at Ashdar Building, 90 Yigal Alon Street, Tel Aviv, Israel, where it was founded in 1987. SHL Telemedicine maintains collaborations with Mayo Clinic for SmartHeart post-heart attack evaluation, Hebrew University of Jerusalem, and Hadassah Medical Center; recent SEC filings reflect ongoing operational reports and employee securities registrations as of early 2025, with no major acquisitions or funding rounds announced in the past two years.